Revenue momentum Novartis Institutes for BioMedical Research shows strong and growing revenue signals across global markets, including recent quarterly gains and profitability improvements in regional subsidiaries, indicating a favorable environment for expanded collaboration, tools adoption, and contract expansion.

Global footprint With a large workforce (>10k) and a multinational presence, there are sizable opportunities to tailor enterprise solutions, compliance, and security platforms across multiple regions and functions to support research, manufacturing, and commercial activities.

Tech stack maturity Existing investments in diverse tools (Checkmarx, Terraform, Android Studio, Asana, LabVIEW, etc.) signal a readiness to integrate sophisticated development, security, project management, and automation solutions that align with their bio pharmaceutical R&D and manufacturing workflows.

R&D and radiopharma focus Active development in radiopharmaceutical candidates such as Ac-PSMA-617 and other late-stage programs suggests opportunities to offer specialized data management, imaging analytics, regulatory submission tooling, and high-assurance cloud solutions to accelerate trials and manufacturing readiness.

Strategic leadership shifts Recent leadership changes in government affairs and regional leadership transitions highlight a potential window to introduce stakeholder engagement platforms, policy monitoring, and collaboration tools that support rapid alignment with evolving regulatory and market access strategies.